Untreated Clinical Trials

1 recruiting

Untreated Trials at a Glance

14 actively recruiting trials for untreated are listed on ClinicalTrialsFinder across 6 cities in 33 countries. The largest study group is Phase 2 with 9 trials, with the heaviest enrollment activity in Houston, Columbus, and Baltimore. Lead sponsors running untreated studies include M.D. Anderson Cancer Center, Bristol-Myers Squibb, and Beat AML, LLC.

Browse untreated trials by phase

Treatments under study

About Untreated Clinical Trials

Looking for clinical trials for Untreated? There are currently 1 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Untreated trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Untreated clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 114 of 14 trials

Recruiting
Phase 3

A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients

Untreated Follicular Lymphoma
AstraZeneca1,018 enrolled159 locationsNCT06549595
Recruiting
Phase 2Phase 3

A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)

Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
Bristol-Myers Squibb690 enrolled160 locationsNCT07221149
Recruiting
Phase 2Phase 3

A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer

Untreated, Unresectable, or Metastatic Colorectal Cancer
Bristol-Myers Squibb990 enrolled263 locationsNCT07221357
Recruiting
Phase 2

Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

High Risk Myelodysplastic SyndromeMyelodysplastic Syndrome With Excess Blastsde Novo Myelodysplastic Syndrome+7 more
M.D. Anderson Cancer Center270 enrolled1 locationNCT00801489
Recruiting
Phase 3

A Phase III Study of SHR-A1811 in Combination With Chemotherapy and Adebrelimab in Previously Untreated Patients With Gastric or Gastroesophageal Junction Adenocarcinoma

Patients With Unresectable Locally Advanced or Metastatic Untreated Gastric or Gastroesophageal Junction Adenocarcinoma
Suzhou Suncadia Biopharmaceuticals Co., Ltd.600 enrolled2 locationsNCT07118527
Recruiting
Phase 3

Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen

Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen
Servier Bio-Innovation LLC136 enrolled114 locationsNCT06127407
Recruiting
Phase 1Phase 2

Study of Biomarker-Based Treatment of Acute Myeloid Leukemia

Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
Beat AML, LLC3,000 enrolled19 locationsNCT03013998
Recruiting
Phase 2

Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia

Acute Myeloid LeukemiaMyelodysplastic SyndromeBlast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive+11 more
M.D. Anderson Cancer Center508 enrolled1 locationNCT02115295
Recruiting
Phase 1

Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation

Myelodysplastic SyndromesRelapsed or Refractory Acute Myeloid Leukemia (AML)Untreated AML+1 more
Institut de Recherches Internationales Servier291 enrolled30 locationsNCT02074839
Recruiting
Phase 2

Orelabrutinib Combined With Zuberitamab in the Initial Treatment of MZL

Initial MZLUntreated MZLBTKi+1 more
Li Zhiming33 enrolled2 locationsNCT06985472
Recruiting
Phase 3

A Clinical Study of JMT101 in Combination With Osimertinib Versus Osimertinib Alone as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Sensitive Mutations

Locally Advanced or Metastatic Non-squamous NSCLCHarboring EGFR Sensitive Mutations NSCLCPreviously Untreated Systematically NSCLC
Shanghai JMT-Bio Inc.516 enrolled1 locationNCT06735391
Recruiting
Phase 2

First-line CBDCA/PTX/LEN/Pembrolizumab Combination for Previously Untreated Advanced or Recurrent Thymic Carcinomas (Artemis)

Untreated Advanced or Recurrent Thymic Carcinomas
National Cancer Center, Japan35 enrolled1 locationNCT05832827
Recruiting
Phase 1Phase 2

Lenalidomide in Combination With R-DA-EPOCH in Patients With Untreated DLBCL With MYC Rearrangement

DLBCLUntreatedMYC Gene Rearrangement
The First Affiliated Hospital with Nanjing Medical University81 enrolled1 locationNCT04432714
Recruiting
Phase 2

A Phase II trial of bortezomib and dexamethasone in renally-impaired patients with untreated multiple myeloma.

Untreated Multiple Myeloma patients with renal impairment.
Prof. Andrew Spencer28 enrolled1 locationACTRN12611000605998